Business Wire

Unifrax and Clearlake Announce Battery Advisory Board to Support Breakthrough Silicon Fiber Anode Battery Technology, Thermal Run-Away and Separator Products

Share

Unifrax, a leading manufacturer of high-performance specialty materials, today introduced its Battery Advisory Board, which will meet regularly to provide strategic guidance as Unifrax grows its battery portfolio and enters the silicon anode market with its new SiFAB™ Silicon Fiber Anode Battery Technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211111005282/en/

SiFAB, a scalable proprietary silicon anode battery technology demonstrated in wide-reaching applications, including electric vehicles, power tools, smartphones, personal computers, medical devices and aviation, can deliver up to 20% increase in gravimetric energy density in lithium-ion batteries. It has proven through advanced testing high reversible capacity of greater than 1,000 mAh/g. Unifrax recently broke ground on its first production line located in New Carlisle, IN, which is expected to come online in early 2022.

This transformational technology becomes part of a robust battery portfolio that also consists of world class thermal management products and separator media.

The advisory board will bring together four highly experienced professionals and visionaries in the battery technology, engineering and operations space, with experts from the nation’s top universities and esteemed technology companies.

Unifrax’s Battery Advisory Board will include:

  • Dr. Prabhakar Patil, former CEO, LG Chem Power, and Chief Engineer of Hybrid Technologies, Ford Motor Company. Dr. Patil previously served as CEO of LG Chem Power (LGCPI) for 10 years. Prior to joining LGCPI in 2005, Dr. Patil spent 27 years of his professional career at Ford Motor Company in various engineering and management positions. He served as Chief Engineer for Ford’s hybrid technologies during 2003 and was also Chief Engineer for the Ford Escape Hybrid from 1998 to 2003.
  • Rita Lane, former Vice President of Operations, Apple Inc., and Senior Vice President of Integrated Supply Chain, Motorola. Ms. Lane has more than 30 years of experience building and leading global hardware operations and supply chain teams for Fortune 100 companies. From 2008 until her retirement in 2014, she served as Vice President of Operations at Apple, where she oversaw the launch of the iPad and manufacturing of the Mac desktop and accessories product lines. From 2006 to 2008, Lane was Chief Procurement Officer and SVP, Supply Chain, at Motorola. Prior to working at Motorola, Lane held various senior-level operations roles at IBM for more than 10 years.
  • Dr. Arumugam “Ram” Manthiram, Professor, University of Texas at Austin. Dr. Manthiram is Director of the Texas Materials Institute and the Materials Science and Engineering Graduate Program. With more than 35 years of experience, Dr. Manthiram’s research is focused on the development of low-cost, high-performance materials for batteries. He is a globally recognized leader in cathode materials for lithium-ion batteries. He has authored more than 850 journal articles. Dr. Manthiram holds the Cockrell Family Regents Chair in Engineering #5. He delivered the lecture on behalf of Nobel Prize recipient John B. Goodenough in 2019 in Stockholm for his work on lithium-ion batteries.
  • Dr. Jennifer Rupp, Professor of Electrochemical Materials, Massachusetts Institute of Technology (MIT) and TU Munich (TUM). Dr. Rupp is Associate Professor of Electrochemical Materials in the Departments of Materials Science and Engineering at MIT and in the Department of Chemistry at TUM, and technical director of TUM Int. Energy. Dr. Rupp gave keynote lectures at Nature Energy and Sustainability conferences, Gordon Research keynote lectures in ceramics and electrochemistry and at the Royal Chemical Society, and presented on battery, information and energy technology at the World Economic Forum. Dr. Rupp’s team's current research focuses are on solid-state material design and tuning of structure-property relations for novel energy and information devices and operation schemes. In 2021, Rupp was invited to become a Fellow of the Royal Society of Chemistry (FRSC).

“We’re thrilled to have put together such a talented and influential advisory board,” said John Dandolph, CEO, Unifrax. “Their depth of experience and perspective in lithium-ion battery technology and novel chemistries spans multiple industries, including portable electronics, consumer devices and EVs, which will help us navigate the complex supply chains as we bring hundreds of metric tons of capacity to the market in the near future. I look forward to partnering with this group of industry icons as we transform battery safety, capacity, power, and charge times.”

To learn more about SiFAB or to follow the latest updates on the technology, visit www.sifab.com.

About Unifrax

Unifrax develops and manufactures high-performance specialty materials used in advanced applications, including high-temperature industrial insulation, electric vehicles, energy storage, filtration and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has over 60 global manufacturing facilities and employs 5,600+ employees globally. More information is available at www.unifrax.com. For updates, follow us on Twitter, LinkedIn and Facebook.

About Clearlake

Clearlake Capital Group, L.P. is a leading investment firm founded in 2006 operating integrated businesses across private equity, credit, and other related strategies. With a sector-focused approach, the firm seeks to partner with world-class management teams by providing patient, long-term capital to dynamic businesses that can benefit from Clearlake’s operational improvement approach, O.P.S. ® The firm’s core target sectors are technology, industrials, and consumer. Clearlake currently has approximately $50 billion of assets under management and its senior investment principals have led or co-led over 300 investments. The firm has offices in Santa Monica and Dallas. More information is available at www.clearlake.com and on Twitter @ClearlakeCap.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
For Unifrax:
Deborah L. Myers
Director, Global Marketing Communication
dmyers@unifrax.com
716.812.4802

For Clearlake:
Jennifer Hurson
Lambert & Co.
jhurson@lambert.com
845.507.0571

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release

Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye